Welcome to our dedicated page for 2Seventy Bio SEC filings (Ticker: TSVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The 2seventy bio (TSVT) SEC filings page on Stock Titan is intended to aggregate the company’s regulatory disclosures as they become available from the U.S. Securities and Exchange Commission’s EDGAR system. While no specific filings are listed in the provided data, investors typically look to these documents for detailed information on financial performance, risk factors, collaborations, and significant corporate events affecting 2seventy bio’s business.
As an immuno-oncology cell therapy company focused on Abecma (idecabtagene vicleucel; ide-cel) for relapsed or refractory multiple myeloma, 2seventy bio uses its SEC reports to describe its collaboration with Bristol Myers Squibb (BMS), including the structure under which the companies share equally in all profits and losses related to the development, manufacturing, and commercialization of Abecma in the United States, as referenced in company news releases. Filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q typically expand on topics highlighted in press releases, including revenue from collaboration arrangements, research and development spending, selling, general and administrative expenses, and cash, cash equivalents, and marketable securities.
Given 2seventy bio’s announced definitive merger agreement to be acquired by Bristol Myers Squibb in an all-cash transaction, investors may also expect to find transaction-related disclosures in SEC filings, such as tender offer documents and merger-related statements, which elaborate on terms, conditions, and anticipated outcomes of the deal. Company communications indicate that, following completion of the tender offer and a second-step merger, 2seventy bio’s common stock will no longer be listed on Nasdaq.
On Stock Titan, TSVT filings are complemented by AI-powered summaries that help explain the key points of lengthy documents, such as 10-K and 10-Q reports, in more accessible language. As new filings are posted to EDGAR, they can be surfaced in near real time, allowing users to review financial updates, collaboration details, risk discussions, and any insider transaction reports (such as Forms 4) that may become available. This combination of primary SEC documents and AI-generated overviews can assist users in understanding how regulatory disclosures align with the trends and statements highlighted in 2seventy bio’s news releases.
Glazer Capital, LLC and Paul J. Glazer filed a Schedule 13G/A regarding 2seventy bio's common stock. The filing discloses that neither Glazer Capital nor Mr. Glazer beneficially own any shares of the company's common stock, reporting 0 shares (0.00%) and no sole or shared voting or dispositive power. The statement classifies Glazer Capital as an investment adviser/other and Mr. Glazer as an individual reporting person, and includes a certification that the securities were not acquired to influence control of the issuer. This filing is a routine ownership disclosure rather than an acquisition or control notice.
The reporting persons — Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP and David A. Witkin — submitted a Schedule 13G/A with respect to 2seventy bio, Inc.'s common stock. Each reporting person disclaims beneficial ownership except to the extent of any pecuniary interest and reports zero shares and 0% ownership. The cover information lists reporting-person classifications including IA, OO, PN, HC, and IN.
The filing contains certifications that the securities were acquired and are held in the ordinary course of business and were not acquired to influence control. The submission states no sole or shared voting or dispositive power for any reporting person and attaches Exhibit 99.1 (agreement regarding joint filing).
2seventy bio, Inc. Schedule 13G/A shows The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly report beneficial ownership of 308 shares of the issuer's common stock. The filers state no sole voting or dispositive power and report shared voting power of 133 shares and shared dispositive power of 308 shares. The reported amount represents 0.0% of the class and is described as ownership of 5% or less. The filers certify the securities are held in the ordinary course of business and not for the purpose of changing control. The filing includes a joint filing agreement and identifies GS Group as a parent holding company with Goldman Sachs as a subsidiary broker-dealer and investment adviser.